FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

AVEVA Drug Delivery Systems Buprenorphine Transdermal System Recall

Buprenorphine Transdermal System, CIII 10 mcg/hour, 4 Transdermal Systems One package o…

AVEVA Drug Delivery Systems, Inc. · Miramar, FL

Risk level
Class III
Reported by FDA
Mar 22, 2023
Recall ID
D-0465-2023
Check your lot numberHow we source this data

Summary

AVEVA Drug Delivery Systems recalled Buprenorphine Transdermal System starting Feb 15, 2023. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0465-2023 on Mar 22, 2023. Reason: Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint. Status: Terminated.

Why it was recalled

Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint.

Product description

Buprenorphine Transdermal System, CIII 10 mcg/hour, 4 Transdermal Systems One package of 4 disposal units, Rx Only, Manufactured by: Aveva Drug Delivery Systems Inc. Miramar, FL. 33025, Manufactured for: Apotex Corp Weston, FL. 33326, NDC 60505-7077-05

Lot numbers, UPCs & expiration codes

Lot#: 51835 Exp: 06/2023

Where it was sold

Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0465-2023
Classification
Class III
Status
Terminated
Recall initiated
Feb 15, 2023
FDA report date
Mar 22, 2023
Quantity
11,520 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
AVEVA Drug Delivery Systems, Inc.

Original FDA data

Every field from FDA enforcement report D-0465-2023, exactly as published.

Show all FDA fields
City
Miramar
State
FL
Status
Terminated
Country
United States
Event ID
91712
Address
3250 Commerce Pkwy
Code information
Lot#: 51835 Exp: 06/2023
Postal code
33025-3907
Report date
Mar 22, 2023
Product type
Drugs
Recall number
D-0465-2023
Classification
Class III
Recalling firm
AVEVA Drug Delivery Systems, Inc.
Product quantity
11,520 cartons
Termination date
Apr 30, 2024
Reason for recall
Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Buprenorphine Transdermal System, CIII 10 mcg/hour, 4 Transdermal Systems One package of 4 disposal units, Rx Only, Manufactured by: Aveva Drug Delivery Systems Inc. Miramar, FL. 33025, Manufactured for: Apotex Corp Weston, FL. 33326, NDC 60505-7077-05
Distribution pattern
Nationwide
Recall initiation date
Feb 15, 2023
Initial firm notification
Letter
Center classification date
Mar 14, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0465-2023, published Mar 22, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls